SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for STOK.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
March 31, 2026 19.97M
December 31, 2025 21.15M
September 30, 2025 16.03M
June 30, 2025 15.26M
March 31, 2025 14.65M
December 31, 2024 12.84M
September 30, 2024 12.69M
June 30, 2024 13.04M
March 31, 2024 10.22M
December 31, 2023 10.61M
September 30, 2023 10.27M
June 30, 2023 10.23M
March 31, 2023 10.21M
December 31, 2022 9.383M
September 30, 2022 9.944M
June 30, 2022 10.11M
March 31, 2022 9.486M
Date Value
December 31, 2021 8.724M
September 30, 2021 8.325M
June 30, 2021 7.934M
March 31, 2021 6.914M
December 31, 2020 5.682M
September 30, 2020 5.602M
June 30, 2020 5.044M
March 31, 2020 4.52M
December 31, 2019 3.979M
September 30, 2019 3.324M
June 30, 2019 2.422M
March 31, 2019 2.189M
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.66M

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Recursion Pharmaceuticals, Inc. 34.59M
Agenus, Inc. 6.86M
Amgen, Inc. 1.602B
BioCryst Pharmaceuticals, Inc. 94.55M
Imunon, Inc. 1.969M